SG11201408173WA - Pyrimidinyl tyrosine kinase inhibitors - Google Patents

Pyrimidinyl tyrosine kinase inhibitors

Info

Publication number: SG11201408173WA
Authority: SG; Singapore
Prior art keywords: massachusetts; international; road; boston; biogen idec
Prior art date: 2012-06-08

Application number

SG11201408173WA

Other languages

English (en)

Inventor

Brian T Hopkins

Patrick Conlon

Timothy R Chan

Tracy J Jenkins

Xiongwei Cai

Michael Humora

Xianglin Shi

Ross A Miller

Andrew Thompson

Original Assignee

Biogen Idec Inc

Sunesis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-08

Filing date

2013-06-07

Publication date

2015-01-29

2013-06-07 Application filed by Biogen Idec Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Idec Inc

2015-01-29 Publication of SG11201408173WA publication Critical patent/SG11201408173WA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

SG11201408173WA 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors SG11201408173WA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261657360P	2012-06-08	2012-06-08
PCT/US2013/044800 WO2013185084A1 (en)	2012-06-08	2013-06-07	Pyrimidinyl tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
SG11201408173WA true SG11201408173WA (en)	2015-01-29

Family

ID=49712704

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201408173WA SG11201408173WA (en)	2012-06-08	2013-06-07	Pyrimidinyl tyrosine kinase inhibitors
SG10201708535UA SG10201708535UA (en)	2012-06-08	2013-06-07	Pyrimidinyl tyrosine kinase inhibitors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201708535UA SG10201708535UA (en)	2012-06-08	2013-06-07	Pyrimidinyl tyrosine kinase inhibitors

Country Status (30)

Country	Link
US (5)	US9394277B2 (es)
EP (3)	EP2858499B1 (es)
JP (6)	JP6214643B2 (es)
KR (4)	KR20220154850A (es)
CN (3)	CN113549055A (es)
AR (1)	AR091273A1 (es)
AU (5)	AU2013271407B2 (es)
BR (2)	BR122021002178B1 (es)
CA (2)	CA3108186A1 (es)
CY (1)	CY1120638T1 (es)
DK (1)	DK2858499T3 (es)
EA (2)	EA027823B1 (es)
ES (2)	ES2684268T3 (es)
HK (1)	HK1209284A1 (es)
HR (1)	HRP20181294T1 (es)
HU (1)	HUE039897T2 (es)
IL (2)	IL235938B (es)
IN (1)	IN2014DN10576A (es)
LT (1)	LT2858499T (es)
MX (2)	MX363672B (es)
NZ (1)	NZ702715A (es)
PH (2)	PH12014502699B1 (es)
PL (1)	PL2858499T3 (es)
PT (1)	PT2858499T (es)
RS (1)	RS57978B1 (es)
SG (2)	SG11201408173WA (es)
SI (1)	SI2858499T1 (es)
TW (3)	TWI792158B (es)
WO (1)	WO2013185084A1 (es)
ZA (1)	ZA201409255B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2473049T3 (en)	2009-09-04	2019-04-01	Biogen Ma Inc	INHIBITORS OF BRUTON'S TYROSINKINASE
EP2632898A4 (en)	2010-10-29	2014-04-02	Biogen Idec Inc	HETEROCYCLIC TYROSINE KINASE HEMMER
AR091273A1 (es)	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
WO2013185082A2 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Inhibitors of bruton's tyrosine kinase
JP6431914B2 (ja) *	2013-12-11	2018-11-28	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物
WO2015151006A1 (en)	2014-03-29	2015-10-08	Lupin Limited	Substituted purine compounds as btk inhibitors
WO2015170266A1 (en)	2014-05-07	2015-11-12	Lupin Limited	Substituted pyrimidine compounds as btk inhibitors
SG10201903578VA (en)	2014-10-24	2019-05-30	Bristol Myers Squibb Co	Indole carboxamides compounds useful as kinase inhibitors
BR112019001158A2 (pt)	2016-07-21	2019-04-30	Biogen Ma, Inc.	formas de succinato e composições de inibidores da tirosina quinase de bruton
US20210113568A1 (en)	2018-04-27	2021-04-22	Ono Pharmaceutical Co., Ltd.	PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
CA3108065A1 (en)	2018-07-31	2020-02-06	Loxo Oncology, Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US20240100172A1 (en)	2020-12-21	2024-03-28	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
WO2022212893A1 (en)	2021-04-02	2022-10-06	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
WO2023081709A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Vecabrutinib for the treatment of graft-versus-host disease
WO2023081715A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023110970A1 (en)	2021-12-14	2023-06-22	Netherlands Translational Research Center Holding B.V	Macrocyclic btk inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1624A (en) *		1840-06-10		Cooking-stove
US4528138A (en)	1984-06-20	1985-07-09	E. R. Squibb & Sons, Inc.	16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en)	1986-07-30	1990-03-27	Alcon Laboratories, Inc.	Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr)	1985-10-03	1988-12-02	Merck Sharp & Dohme	Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de)	1991-01-15	1997-03-06	Alcon Lab Inc	Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en)	1991-03-27	1993-05-18	Alcon Laboratories, Inc.	Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en)	2000-11-21	2005-07-19	Sunesis Pharmaceuticals, Inc.	Extended tethering approach for rapid identification of ligands
CN1481377A (zh)	2000-03-17	2004-03-10	��˹�ж�-��˹˹��ҩƷ��˾	作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
MY137020A (en)	2000-04-27	2008-12-31	Abbott Lab	Diazabicyclic central nervous system active agents
CZ20023993A3 (cs)	2000-06-26	2004-02-18	Pfizer Products Inc.	Pyrolo [2,3-d]pyrimidinové sloučeniny jako imunosupresivní činidla
PE20020507A1 (es) *	2000-10-17	2002-06-25	Schering Corp	Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2003037271A2 (en) *	2001-10-30	2003-05-08	Millennium Pharmaceuticals,Inc.	Compounds, pharmaceutical compositions and methods of use therefor
CA2464934A1 (en)	2001-10-31	2003-05-08	Bayer Healthcare Ag	Pyrimido [4,5-b] indole derivatives
EP1599468B1 (en)	2003-01-14	2007-10-03	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP1678166B1 (en)	2003-10-14	2009-07-29	The Arizona Board of Regents on Behalf of the University of Arizona	Protein kinase inhibitors
EP1778298A4 (en) *	2004-04-01	2010-03-31	Univ Pennsylvania	LIPOPROTEIN-NANO PLATFORMS
WO2005117909A2 (en)	2004-04-23	2005-12-15	Exelixis, Inc.	Kinase modulators and methods of use
FR2870541B1 (fr)	2004-05-18	2006-07-14	Proskelia Sas	Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en)	2004-09-09	2006-07-01	Mitsubishi Pharma Corp	2-morpholino-4-pyrimidone compound
AU2005304784B2 (en) *	2004-11-04	2011-03-24	Vertex Pharmaceuticals Incorporated	Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JP5254620B2 (ja)	2004-12-03	2013-08-07	メルク・シャープ・アンド・ドーム・コーポレーション	Ｃｂ１アンタゴニストとしての置換ピペラジン
EP1848719B1 (en)	2004-12-28	2012-02-01	Exelixis, Inc.	[1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006071875A1 (en)	2004-12-29	2006-07-06	Millennium Pharmaceuticals, Inc.	Compounds useful as chemokine receptor antagonists
US7423043B2 (en)	2005-02-18	2008-09-09	Lexicon Pharmaceuticals, Inc.	4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281700A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en)	2005-06-10	2006-12-14	Gaul Michael D	Aminopyrimidines as kinase modulators
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
BR122021011787B1 (pt)	2005-11-01	2022-01-25	Impact Biomedicines, Inc	Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
EP1965862A2 (en) *	2005-12-21	2008-09-10	Schering Corporation	Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2008005368A2 (en)	2006-06-30	2008-01-10	Abbott Laboratories	Piperazines as p2x7 antagonists
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
US20090325948A1 (en)	2006-07-26	2009-12-31	Timothy Brian Hurley	Inhibitors of undecaprenyl pyrophosphate synthase
US20100160292A1 (en)	2006-09-11	2010-06-24	Cgi Pharmaceuticals, Inc	Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
KR101315610B1 (ko) *	2006-09-22	2013-10-10	파마시클릭스, 인코포레이티드	브루톤 티로신 키나제 억제제
TW200840571A (en) *	2007-03-02	2008-10-16	Schering Corp	Piperidine derivatives and methods of use thereof
JP2010522241A (ja)	2007-03-21	2010-07-01	ブリストル−マイヤーズスクイブカンパニー	増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
BRPI0811898A2 (pt)	2007-06-01	2019-09-24	Glaxosmithkline Llc	composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto.
SI2242749T1 (sl) *	2008-02-05	2013-07-31	F.Hoffmann-La Roche Ag	Novi piridinoni in piridazinoni
JP2011519049A (ja)	2008-04-29	2011-06-30	イミューンエクサイトインコーポレイテッド	免疫調節組成物およびその使用方法
ES2660418T3 (es)	2008-07-16	2018-03-22	Pharmacyclics Llc	Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
WO2010068788A1 (en) *	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Heterocyclic amides as btk inhibitors
WO2010080481A1 (en) *	2008-12-19	2010-07-15	Bristol-Myers Squibb Company	Carbazole carboxamide compounds useful as kinase inhibitors
US9266890B2 (en) *	2009-01-06	2016-02-23	Dana-Farber Cancer Institute, Inc.	Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US9096610B2 (en)	2009-05-25	2015-08-04	Sandoz Ag	Method for the production of ceftobiprole medocaril
DK2473049T3 (en)	2009-09-04	2019-04-01	Biogen Ma Inc	INHIBITORS OF BRUTON'S TYROSINKINASE
WO2011029043A1 (en)	2009-09-04	2011-03-10	Biogen Idec Ma Inc.	Heteroaryl btk inhibitors
US8685880B2 (en) *	2010-06-30	2014-04-01	Chevron U.S.A. Inc.	On-site drying of aqueous salt for ionic liquid make-up
EP2632898A4 (en)	2010-10-29	2014-04-02	Biogen Idec Inc	HETEROCYCLIC TYROSINE KINASE HEMMER
WO2013185082A2 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Inhibitors of bruton's tyrosine kinase
AR091273A1 (es) *	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
JP6431914B2 (ja)	2013-12-11	2018-11-28	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物
EP3444251B1 (en)	2013-12-11	2023-06-07	Biogen MA Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016054627A1 (en)	2014-10-03	2016-04-07	Ohio State Innovation Foundation	Biomarkers of bruton tyrosine kinase inhibitor resistance

2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en active Application Filing
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh active
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Application Discontinuation
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en unknown
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko active IP Right Grant
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh active Active
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh active
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en active Pending
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active IP Right Grant
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja active Active
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt active IP Right Grant
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko active Application Filing
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en active Active
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en active Active
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh active
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699B1/en unknown
- 2014-12-08 MX MX2019003618A patent/MX2019003618A/es unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
2015
- 2015-10-20 HK HK15110301.6A patent/HK1209284A1/xx unknown
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en active Active
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-07-09 PH PH12018501463A patent/PH12018501463A1/en unknown
- 2018-08-08 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en active Active
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
2021
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en active Pending
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en active Pending
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending

Also Published As

Publication number	Publication date
AU2017201536A1 (en)	2017-03-23
EP3385263B1 (en)	2020-07-22
AU2019203476A1 (en)	2019-06-06
AU2013271407A1 (en)	2015-01-22
EP2858499A4 (en)	2016-01-20
MX2019003618A (es)	2019-07-18
US20150158843A1 (en)	2015-06-11
CN109305959B (zh)	2022-02-08
AU2019203476B2 (en)	2021-01-28
AU2022275504A1 (en)	2023-01-05
JP2019077728A (ja)	2019-05-23
US10618887B2 (en)	2020-04-14
US9394277B2 (en)	2016-07-19
JP2021073299A (ja)	2021-05-13
KR20210072139A (ko)	2021-06-16
EP3385263A1 (en)	2018-10-10
SG10201708535UA (en)	2017-11-29
ZA201409255B (en)	2015-12-23
DK2858499T3 (en)	2018-08-20
JP2021073298A (ja)	2021-05-13
CA2875799C (en)	2021-03-23
IL235938A0 (en)	2015-02-01
TW201410668A (zh)	2014-03-16
TW202142535A (zh)	2021-11-16
PT2858499T (pt)	2018-10-24
IN2014DN10576A (es)	2015-08-28
US20160304494A1 (en)	2016-10-20
PH12014502699A1 (en)	2015-02-02
TWI592406B (zh)	2017-07-21
EP2858499B1 (en)	2018-05-16
IL235938B (en)	2020-10-29
US20210017155A1 (en)	2021-01-21
BR122021002178B1 (pt)	2022-03-22
JP2023052415A (ja)	2023-04-11
CN104540385B (zh)	2018-06-05
JP2015518903A (ja)	2015-07-06
AU2021202412A1 (en)	2021-05-20
TW201805279A (zh)	2018-02-16
EP3753934A1 (en)	2020-12-23
CN104540385A (zh)	2015-04-22
KR20150036020A (ko)	2015-04-07
CN109305959A (zh)	2019-02-05
AU2013271407B2 (en)	2016-12-08
TWI792158B (zh)	2023-02-11
MX2014015044A (es)	2015-09-22
US20230174511A1 (en)	2023-06-08
ES2834333T3 (es)	2021-06-17
AU2017201536B2 (en)	2019-03-07
EA201790418A1 (ru)	2017-11-30
TWI719209B (zh)	2021-02-21
PH12018501463A1 (en)	2019-03-04
KR20220154850A (ko)	2022-11-22
RS57978B1 (sr)	2019-01-31
BR112014030655A8 (pt)	2018-01-02
HRP20181294T1 (hr)	2018-10-05
EA027823B1 (ru)	2017-09-29
JP2017193583A (ja)	2017-10-26
EP2858499A1 (en)	2015-04-15
EA201492056A1 (ru)	2015-05-29
AR091273A1 (es)	2015-01-21
KR102468430B1 (ko)	2022-11-21
KR102102587B1 (ko)	2020-04-22
US9944622B2 (en)	2018-04-17
PH12014502699B1 (en)	2015-02-02
PL2858499T3 (pl)	2019-03-29
CN113549055A (zh)	2021-10-26
LT2858499T (lt)	2018-09-10
MX363672B (es)	2019-03-29
BR112014030655A2 (pt)	2017-06-27
IL277951A (en)	2020-11-30
KR20200043497A (ko)	2020-04-27
WO2013185084A1 (en)	2013-12-12
CA3108186A1 (en)	2013-12-12
CY1120638T1 (el)	2019-12-11
ES2684268T3 (es)	2018-10-02
NZ702715A (en)	2016-11-25
CA2875799A1 (en)	2013-12-12
US20190047986A1 (en)	2019-02-14
HK1209284A1 (en)	2016-04-01
JP6214643B2 (ja)	2017-10-18
SI2858499T1 (sl)	2018-10-30
BR112014030655B1 (pt)	2021-04-20
HUE039897T2 (hu)	2019-02-28

Publication	Publication Date	Title
SG11201408173WA (en)	2015-01-29	Pyrimidinyl tyrosine kinase inhibitors
SG11201804170RA (en)	2018-06-28	Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201908560SA (en)	2019-10-30	Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201809082WA (en)	2018-11-29	Nlrp3 modulators
SG11201907544VA (en)	2019-09-27	Jak inhibitors containing a 4-membered heterocyclic amide
SG11202000105QA (en)	2020-02-27	Anti-cd166 antibodies and uses thereof
SG11201900799XA (en)	2019-02-27	Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201808990QA (en)	2018-11-29	Compositions for topical application of compounds
SG11201906192SA (en)	2019-08-27	Methods of treating cancer with anti-pd-1 antibodies
SG11201408094YA (en)	2015-01-29	Neprilysin inhibitors
SG11201407580YA (en)	2014-12-30	Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407228PA (en)	2014-12-30	N-aryltriazole compounds as lpar antagonists
SG11201811230RA (en)	2019-01-30	Compositions and methods for reducing ocular neovascularization
SG11201803920TA (en)	2018-06-28	Compounds and compositions useful for treating disorders related to ntrk
SG11201900745VA (en)	2019-02-27	Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201407220YA (en)	2014-12-30	N-alkyltriazole compounds as lpar antagonists
SG11201805380YA (en)	2018-07-30	Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
SG11201907889YA (en)	2019-09-27	Glycan-interacting compounds and methods of use
SG11201902886SA (en)	2019-05-30	Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201408095XA (en)	2015-01-29	Fibroblast growth factor 21 proteins
SG11201908326YA (en)	2019-10-30	Methods of treating neurodegenerative diseases
SG11201809751XA (en)	2018-12-28	Egfr inhibitor compounds
SG11201908512YA (en)	2019-10-30	Somatostatin modulators and uses thereof
SG11201907364WA (en)	2019-09-27	Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201903061YA (en)	2019-05-30	Combination treatments comprising administration of imidazopyrazinones